Patents by Inventor Brendan Christian BENDER

Brendan Christian BENDER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DOSING FOR TREATMENT WITH ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODIES
    Publication number: 20220162329
    Abstract: The present invention relates to the treatment of subjects having CD20-positive cell proliferative disorders (e.g., B cell proliferative disorders, such as non-Hodgkin's lymphomas). More specifically, the invention pertains to the treatment of subjects having a B cell proliferative disorder by intravenous administration of an anti-CD20/anti-CD3 bispecific antibody (e.g., mosunetuzumab).
    Type: Application
    Filed: November 2, 2021
    Publication date: May 26, 2022
    Inventors: Chi-Chung LI, Carol Elaine O'HEAR, Brendan Christian BENDER
  • SUBCUTANEOUS DOSING OF ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODIES
    Publication number: 20220153858
    Abstract: The present invention relates to the treatment of subjects having CD20-positive cell proliferative disorders (e.g., B cell proliferative disorders, such as non-Hodgkin's lymphomas). More specifically, the invention pertains to the treatment of subjects having a B cell proliferative disorder by subcutaneous administration of an anti-CD20/anti-CD3 bispecific antibody.
    Type: Application
    Filed: November 2, 2021
    Publication date: May 19, 2022
    Inventors: Chi-Chung LI, Carol Elaine O'HEAR, Hong WANG, Brendan Christian BENDER, Iraj HOSSEINI
  • DOSING FOR TREATMENT WITH ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODIES AND ANTI-CD79B ANTIBODY DRUG CONJUGATES
    Publication number: 20220153842
    Abstract: The present invention relates to the treatment of subjects having CD20-positive cell proliferative disorders (e.g., B cell proliferative disorders, such as non-Hodgkin's lymphomas). More specifically, the invention pertains to the treatment of subjects having a CD20-positive cell proliferative disorder (e.g., B cell proliferative disorder) by administering a combination of an anti-CD20/anti-CD3 bispecific antibody and an anti-CD79b antibody drug conjugate.
    Type: Application
    Filed: November 2, 2021
    Publication date: May 19, 2022
    Inventors: Chi-Chung LI, Carol Elaine O'HEAR, Stephen James SIMKO, III, Iris Tranthuyngan TO, Klara TOTPAL, Hong WANG, Michael C. WEI, Shen YIN, Brendan Christian BENDER, Xi CHEN, Yu-Waye CHU, Maria HRISTOPOULOS